These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 34523710)

  • 41. The effect of perazine on the CYP2D6 and CYP2C19 phenotypes as measured by the dextromethorphan and mephenytoin tests in psychiatric patients.
    Baumann P; Eap CB; Gastpar M
    Basic Clin Pharmacol Toxicol; 2020 May; 126(5):444-447. PubMed ID: 31814297
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Utility and adoption of CYP2D6 and CYP2C19 genotyping and its translation into psychiatric clinical practice.
    Jürgens G; Jacobsen CB; Rasmussen HB; Werge T; Nordentoft M; Andersen SE
    Acta Psychiatr Scand; 2012 Mar; 125(3):228-37. PubMed ID: 22128793
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Endoxifen levels and its association with CYP2D6 genotype and phenotype: evaluation of a southern Brazilian population under tamoxifen pharmacotherapy.
    Antunes MV; Linden R; Santos TV; Wallemacq P; Haufroid V; Classen JF; Andreolla H; Costa N; Fontanive TO; Rosa DD
    Ther Drug Monit; 2012 Aug; 34(4):422-31. PubMed ID: 22777153
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Does pharmacogenetic testing for CYP450 2D6 and 2C19 among patients with diagnoses within the schizophrenic spectrum reduce treatment costs?
    Herbild L; Andersen SE; Werge T; Rasmussen HB; Jürgens G
    Basic Clin Pharmacol Toxicol; 2013 Oct; 113(4):266-72. PubMed ID: 23731498
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?
    Løvlie R; Daly AK; Matre GE; Molven A; Steen VM
    Pharmacogenetics; 2001 Feb; 11(1):45-55. PubMed ID: 11207030
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Interferon-beta treatment in patients with multiple sclerosis does not alter CYP2C19 or CYP2D6 activity.
    Hellman K; Roos E; Osterlund A; Wahlberg A; Gustafsson LL; Bertilsson L; Fredrikson S
    Br J Clin Pharmacol; 2003 Sep; 56(3):337-40. PubMed ID: 12919185
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol.
    Lisbeth P; Vincent H; Kristof M; Bernard S; Manuel M; Hugo N
    Eur J Clin Pharmacol; 2016 Feb; 72(2):175-84. PubMed ID: 26514968
    [TBL] [Abstract][Full Text] [Related]  

  • 48. To Genotype or Phenotype for Personalized Medicine? CYP450 Drug Metabolizing Enzyme Genotype-Phenotype Concordance and Discordance in the Ecuadorian Population.
    De Andrés F; Terán S; Hernández F; Terán E; LLerena A
    OMICS; 2016 Dec; 20(12):699-710. PubMed ID: 27849442
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Debrisoquin and S-mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population.
    Marandi T; Dahl ML; Kiivet RA; Rägo L; Sjöqvist F
    Pharmacol Toxicol; 1996 May; 78(5):303-7. PubMed ID: 8737964
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
    Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
    Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serum clomipramine and desmethylclomipramine levels in a CYP2C19 and CYP2D6 intermediate metabolizer.
    Brown JT; Schneiderhan M; Eum S; Bishop JR
    Pharmacogenomics; 2017 May; 18(7):601-605. PubMed ID: 28470111
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacogenetic Testing in Patients with Autism Spectrum Disorder Evaluated in a Precision Medicine Clinic.
    Goodson R; Wagner J; Sandritter T; Staggs VS; Soden S; Nadler C
    J Dev Behav Pediatr; 2023 Oct-Nov 01; 44(8):e505-e510. PubMed ID: 37807195
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An optimized methodology for combined phenotyping and genotyping on CYP2D6 and CYP2C19.
    Tamminga WJ; Wemer J; Oosterhuis B; Brakenhoff JP; Gerrits MG; de Zeeuw RA; de Leij LF; Jonkman JH
    Eur J Clin Pharmacol; 2001 May; 57(2):143-6. PubMed ID: 11417446
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical Impact of Functional CYP2C19 and CYP2D6 Gene Variants on Treatment with Antidepressants in Young People with Depression: A Danish Cohort Study.
    Thiele LS; Ishtiak-Ahmed K; Thirstrup JP; Agerbo E; Lunenburg CATC; Müller DJ; Gasse C
    Pharmaceuticals (Basel); 2022 Jul; 15(7):. PubMed ID: 35890168
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations.
    LLerena A; Naranjo ME; Rodrigues-Soares F; Penas-LLedó EM; Fariñas H; Tarazona-Santos E
    Expert Opin Drug Metab Toxicol; 2014 Nov; 10(11):1569-83. PubMed ID: 25316321
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response.
    Tsai MH; Lin KM; Hsiao MC; Shen WW; Lu ML; Tang HS; Fang CK; Wu CS; Lu SC; Liu SC; Chen CY; Liu YL
    Pharmacogenomics; 2010 Apr; 11(4):537-46. PubMed ID: 20350136
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Does the medication pattern reflect the CYP2D6 genotype in patients with diagnoses within the schizophrenic spectrum?
    Jürgens G; Rasmussen HB; Werge T; Dalhoff K; Nordentoft M; Andersen SE
    J Clin Psychopharmacol; 2012 Feb; 32(1):100-5. PubMed ID: 22198443
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The pharmacogenetics of
    Kee PS; Maggo SDS; Kennedy MA; Chin PKL
    Front Pharmacol; 2023; 14():1080117. PubMed ID: 36895946
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients.
    Yokono A; Morita S; Someya T; Hirokane G; Okawa M; Shimoda K
    J Clin Psychopharmacol; 2001 Dec; 21(6):549-55. PubMed ID: 11763000
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.
    Preskorn SH; Kane CP; Lobello K; Nichols AI; Fayyad R; Buckley G; Focht K; Guico-Pabia CJ
    J Clin Psychiatry; 2013 Jun; 74(6):614-21. PubMed ID: 23541126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.